Audit report: USFDA completes inspection of Natco's Mekaguda API facility with zero observations

Natco Pharma Limited is pleased to announce successful completion of regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12th February, 2018 to 16th February, 2018. The regulatory audit resulted in zero observations (no form 483 issued).